Iyi imwe-center, randomized, double-blind, placebo-controlled controlled phase I kliniki yekudzidza inoronga kunyoresa 56 zvidzidzo kuti zviongorore kushivirira, kuchengeteka uye pharmacokinetic maitiro mushure mekutonga kumwechete / kuwanda muvazvipiri veChinese vane hutano. Muzvinafundo Wang Yongjun, Dean weBeijing Tiantan Hospital, Capital Medical University ndiye mukuru anoongorora. Chidzidzo ichi chakatangwa zviri pamutemo muna Zvita 2, 2021, paine yekutanga dosi yezvidzidzo zvina muboka rekutanga dosing rakapera musi wa4 Zvita.
"Kutanga kwedosing muSimcere yekutanga kiriniki yekudzidza yeSIM0307 nderimwe danho rakakosha kumberi mukusimudzira kwepasirese kweAER-271 apo isu tichitsvaga kurapa kunodiwa, kunobatsira kweacute ischemic sitiroko," akadaro Mike Gresser, Chief Scientific Officer weAeromics. . Gresser akawedzera, "tPA uye mamwe marapirwo ethrombolytic anokonzera kudzokororwa, izvo zvinodiwa, asi kazhinji zvinotungamira mukukuvadzwazve. Kurapa neAER-271 pamwe chete ne thrombolytic therapy kunotarisirwa kubatsira kudzikisa edema nekupindira kutanga mukuzvimba kunobva mukudzokororwa netPA, manual thrombectomy uye kumwe kurapwa kwethrombolytic.
Aeromics naSimcere vakapinda muchibvumirano chekubatana uye chega rezinesi muna Mbudzi 2019 yeAER-271, yekiriniki-nhanho anti-edema therapy inogadzirwa kurapa sitiroko uye zvimwe zviratidzo muGreater China (mainland China, Hong Kong, Macau neTaiwan). Zvinoenderana nechibvumirano, Simcere ichave nebasa rekuvandudza kwekiriniki uye kushambadzira kweAER-271 muGreater China. Muna Kubvumbi 2021, iyo China National Medical Products Administration (NMPA) yakatendera muyedzo wekiriniki weSIM0307 yechiratidzo checerebral edema mushure mekuoma kwakanyanya ischemic sitiroko.
"Tinofara zvikuru kuona SIM0307 ichisvika padanho rakakosha muChina." akadaro Dr. Renhong Tang, Mutungamiriri Mukuru uye Mutevedzeri Mukuru weSimcere, "Kukurumidza kufambira mberi kwemorekuru iyi kunosimbisa matarenda epasi rose eAeromics neSimcere R&D, kukura kwekiriniki, kugadzira, uye kutengeserana."
“Tinoramba tichitenda hukama hwedu naSimcere sezvo zvikwata zvedu zvichishanda zvakasimba kusimudzira chirongwa ichi. Zvese zvataitenda nezve kutsvagisa kwavo, kusimudzira uye kugadzira simba kwakaratidza kuva kwechokwadi, uye kushandirapamwe kwechikwata chavo kwakapfuura zvataitarisira. Tinofara kuona kufambira mberi kwaSimcere apo tiri kugadzirira kutongwa kwedu kwePase IIa proof-of-mechanism muno muUnited States. " akadaro Thomas Zindrick, Executive Chairman Aeromics.
Mutungamiriri Mukuru weSimcere & CEO, VaJinsheng Ren vakapedzisa vachiti, “Tinodada nekugadzira SIM0307 (AER-271), apo tiri kushandura biology inohwina Nobel kuita kurapa kunobatsira varwere vanorwara zvakanyanya vane nzira shoma dzekurapwa. Pamusoro pezvo, SIM0307 ine mukana wekubatanidza nezvimwe zvigadzirwa zviri muSimcere's CNS portfolio seSanbexin® inogona kuwedzera kuvandudza mhedzisiro yevarwere vesitiroko.iyo yakagadziridzwa kuti ishandure . Tinotarisira kufambira mberi kunonakidza mune ramangwana mukubatana pamwe nechikwata cheAeromics. "
